Teacher Retirement System of Texas Trims Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Teacher Retirement System of Texas trimmed its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 9.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,071 shares of the biopharmaceutical company’s stock after selling 1,626 shares during the period. Teacher Retirement System of Texas’ holdings in Celldex Therapeutics were worth $292,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of CLDX. SG Americas Securities LLC boosted its holdings in Celldex Therapeutics by 38.0% in the 1st quarter. SG Americas Securities LLC now owns 34,884 shares of the biopharmaceutical company’s stock worth $633,000 after buying an additional 9,601 shares during the period. Apella Capital LLC bought a new position in Celldex Therapeutics in the 1st quarter worth $309,000. Mirador Capital Partners LP boosted its holdings in Celldex Therapeutics by 7.0% in the 1st quarter. Mirador Capital Partners LP now owns 127,874 shares of the biopharmaceutical company’s stock worth $2,321,000 after buying an additional 8,382 shares during the period. Rhumbline Advisers boosted its holdings in Celldex Therapeutics by 6.9% in the 1st quarter. Rhumbline Advisers now owns 98,266 shares of the biopharmaceutical company’s stock worth $1,784,000 after buying an additional 6,327 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in Celldex Therapeutics by 6,665.9% in the 1st quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 2,933 shares during the period.

Wall Street Analyst Weigh In

CLDX has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Celldex Therapeutics in a report on Friday, June 13th. Canaccord Genuity Group initiated coverage on shares of Celldex Therapeutics in a report on Monday, April 28th. They set a “buy” rating and a $64.00 price objective for the company. The Goldman Sachs Group dropped their price objective on shares of Celldex Therapeutics from $36.00 to $31.00 and set a “neutral” rating for the company in a report on Friday, May 9th. UBS Group lowered their price target on shares of Celldex Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a report on Friday, May 9th. Finally, Morgan Stanley lowered their price target on shares of Celldex Therapeutics from $46.00 to $43.00 and set an “overweight” rating for the company in a report on Friday, May 9th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $50.11.

Celldex Therapeutics Price Performance

Celldex Therapeutics stock opened at $22.41 on Friday. Celldex Therapeutics, Inc. has a 1-year low of $14.40 and a 1-year high of $47.00. The firm has a market capitalization of $1.49 billion, a P/E ratio of -8.30 and a beta of 1.13. The company’s 50-day moving average is $20.87 and its 200 day moving average is $21.02.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). The firm had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $1.08 million. Celldex Therapeutics had a negative return on equity of 23.46% and a negative net margin of 2,366.07%. Research analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.